About the talk
Science has transformed the world of cannabinoids. CBD was once a relatively obscure, banned substance. But scientific research landed this compound in the hands of physicians, engineers, lawmakers, and consumers. In fact, research fuels innovation. Designers rely on emerging scientific evidence to develop cannabinoid products that meet the needs of an evolving market. Where is the science of CBD today? The past year’s breakthroughs in CBD research include medication interactions, epilepsy, neuroscience, dermatological applications, mental health disorders, addiction/relapse, and biochemistry. This council of established scientists will push your company to the cutting edge of chemical/medical advancement in the field. Critics often point out that CBD claims are ahead of the science. But knowledge is power.
23:00 it’s not only about the product
37:05 Lack of understanding of the process
I am an analytical chemist at Kaycha Labs in South Fl. I've worked in various industries from manufacturing, pharmaceutical, academia, and now the CBD/Cannabis industry. My degree is from Florida State University in both Biochemistry and Musical performance. My current role is to ensure products the are being consumed or inhaled in the market have proof of efficacy and are safe from various contaminants; in addition to running an internship program. I, in part, help to lead a team of chemists and create methods to produce quality, reproducible, and reputable results.View the profile
As an alternative to traditional drugs, functional food and dietary supplements can help in the prevention or treatment of several diseases. Based on my education and experience in the fields of nutrition, biochemistry, and molecular biology, I am developing biological assays assessing the real efficiency of natural ingredients. These assays are used for the formulation and validation of claim substantiation. To test the efficacy of natural ingredients and to develop effective nutraceuticals I founded DSTest Laboratories at Purdue Research Park. I published more than 90 scientific peer-reviewed papers, book chapters and articles describing molecular mechanism of activity and efficiency testing of natural products and dietary supplements. I am an invited speaker at international and national scientific meetings where I present recent discoveries how natural compounds improve human health on the cellular level.View the profile
Jessica Barnes graduated from Worcester Polytechnic Institute with a B.S. in Biotechnology, and earned her PhD in Molecular Neuroscience from the University of Illinois at Urbana-Champaign. She was a fellow in the department of pediatric neuro-oncology at the Dana-Farber Cancer Institute and Children’s Hospital Boston under the mentorship of Dr. Judah Folkman. Her roles have including CEO/Co-founder of the 20Lighter Program, Senior Consultant to Valeritas, Inc., Director of New Ventures at Access BridgeGap Ventures, Senior Science Officer at Summer Street Research Partners, and Vice President in MEDACorp at Leerink Swann. Additionally, she provides Business & Corporate Development consulting services to biotech & med device companies.View the profile
Griffin and Griffin Analytical Associates (G2 Analytical) works at the intersection of science and society. Providing robust scientific analysis to real-world applications, it is our goal is to address some of humanity's most challenging analysis problems. To serve our community, we offer analytical test services for pharmaceutical, nutraceutical, environmental, and chemical industries, robust method and product development, and bioanalytical chemistry research. We believe sensing will become pervasive in society as instrumentation and internet-of-things (IoT) continue to evolve. Our goal is to leverage these advances and provide a unified but layered sensing approach from in-situ field measurements to laboratory-based measurements and contribute to a healthier, safer, and more informed community.View the profile
Bill Fisher is the founder and Board Chairman of Diverse Biotech, a biopharmaceutical research company focused on new medical discoveries and the development of new molecules for the treatment of disease. Bill is a creative entrepreneur and executive with over 25 years experience in building businesses in both domestic and global markets. Diverse Biotech executives are some of the most experienced executives from the Pharmaceutical Industry including Merck, Johnson & Johnson, Purdue and many more.View the profile
Included in subscription
I'm Shari. I'm going to be your moderator. Good afternoon. Thanks for joining us. My name is Dr. Jess Barnes a CEO and Co-founder of the 20 Lighter Program. And also I consult to a med device company that is developing a subcutaneous infusion device and one of the opportunities for that is in CBD. Bill Fisher, I am the Chairman of a pharmaceutical company Diverse Biotech and we are in the cannabinoid space in cancer indications and that also is by electives. Good afternoon. My name is Dan Sliva and I'm the Founder of DSTest Laboratories
and we are testing for the real efficacy of natural compounds in CBD. Good afternoon. My name is Todd Griffin. I am the Chief Technical Officer of G2 Analytical. I'm also a Professor of Chemistry at Wingate University in North Carolina. Our company is focused on developing novel detection technologies, including new ways to screen for contamination and for confirming efficacy in CBD products. Big Pharma was watching and it looks like they're getting involved. I thought about your desk. What do you think? I think it's a really exciting area.
Buy this talk
Access to all the recordings of the event
Full access to all published conferences content, valid 12 months